Xalkori (crizotinib) — Medica
Histiocytic Neoplasm (ALK rearrangement/fusion-positive)
Initial criteria
- age ≥ 18 years
- disease is anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive
- EITHER Langerhans cell histiocytosis OR Erdheim-Chester disease OR Rosai-Dorfman disease
Approval duration
1 year